Literature DB >> 10511471

Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study.

F Amenta1, E Bronzetti, L Felici, A Ricci, S K Tayebati.   

Abstract

1. Peripheral blood lymphocytes express dopamine D1-like and D2-like receptors which were investigated using radioligand binding assay and molecular biology techniques. Analysis of dopamine D2-like receptors expressed by human peripheral blood lymphocytes with radioligand binding assay may offer a rapid technique for assessing receptor changes in disorders characterized by involvement of the dopaminergic system. However, the suitability of radioligand binding assay techniques to measure dopamine D2-like receptors is questioned. 2. In view of the discrepancy between data of dopamine D2-like receptor determination with molecular biology and radioligand binding assay techniques, we have assayed dopamine D2-like receptors expressed by human peripheral blood lymphocytes using as radioligands the dopamine receptor agonist 7-[3H]-hydroxy-N,N-di-n-propyl-2-aminotetraline ([3H]-7-OH-DPAT) and two antagonists ([3H]-spiperone and [3H]-nemonapride). 3. Analysis of saturation curves revealed a concentration-dependent binding of all compounds to human peripheral blood lymphocytes. Dissociation constant (Kd) values averaged between 0.15 and 0.40 nM for different radioligands. The maximum density of binding sites (Bmax) was low, ranging from 4.15 +/- 0.05 fmol/10(6) cells with [3H]-spiperone and 8.66 +/- 0.04 fmol/10(6) cells with [3H]-7-OH-DPAT. 4. Displacement curves of [3H]-7-OH-DPAT, [3H]-spiperone and [3H]-nemonapride binding to human peripheral blood lymphocytes revealed, using radioligand concentrations giving the highest specific:non-specific binding ratio, a pharmacological profile consistent with the labelling of dopamine D2-like receptors. The use of higher radioligand concentrations resulted in a poorly displaceable and characterizable binding. 5. Detection of dopamine D2, D3 and D4 receptor immunoreactivity in cytospin centrifuged peripheral blood lymphocytes revealed dopamine D3 and D4 but not D2 receptor immunostaining. 6. The above findings indicate in agreement with molecular biology studies, that dopamine D2-like receptors expressed by human peripheral blood lymphocytes belong to the D3 and D4 receptor subtypes. These receptors are detectable using either dopamine D2-like receptor agonists and antagonists as radioligands if controlled experimental conditions are followed. The standardisation of immunocytochemical techniques for detecting human peripheral blood lymphocyte dopamine receptors may contribute to clarify their role in lymphocyte function or as a peripheral marker of the status of the dopaminergic system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10511471     DOI: 10.1046/j.1365-2680.1999.00135.x

Source DB:  PubMed          Journal:  J Auton Pharmacol        ISSN: 0144-1795


  12 in total

1.  Expression of dopaminergic receptors on human CD4+ T lymphocytes: flow cytometric analysis of naive and memory subsets and relevance for the neuroimmunology of neurodegenerative disease.

Authors:  Natasa Kustrimovic; Emanuela Rasini; Massimiliano Legnaro; Franca Marino; Marco Cosentino
Journal:  J Neuroimmune Pharmacol       Date:  2014-03-29       Impact factor: 4.147

2.  Elevated DISC1 transcript levels in PBMCs during acute psychosis in patients with schizophrenia.

Authors:  Ann Olincy; Robert House; Bifeng Gao; Peter Recksiek; Tzu Lip Phang; Bernadette Sullivan; Jeff P Hollis; Janet Hopkins; Ted Shade; Michael G Edwards; Ruby Vianzon; Cory Griffiths; John Ceilley; Roger W Helfrich; Jonathan Ritvo; Erica Weis; David Weiss; Judith Gault
Journal:  Transl Biomed       Date:  2011

3.  Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia.

Authors:  Amarendra N Singh; Cia Barlas; Huma Saeedi; Ram K Mishra
Journal:  J Psychiatry Neurosci       Date:  2003-01       Impact factor: 6.186

Review 4.  Methamphetamine toxicity and its implications during HIV-1 infection.

Authors:  Peter S Silverstein; Ankit Shah; Raeesa Gupte; Xun Liu; Robert W Piepho; Santosh Kumar; Anil Kumar
Journal:  J Neurovirol       Date:  2011-07-23       Impact factor: 2.643

5.  Dopamine transporter immunoreactivity in peripheral blood lymphocytes in multiple system atrophy.

Authors:  Francesca R Buttarelli; Annapia Circella; Clelia Pellicano; Dorina Tiple; Morena Giovannelli; Carlo Colosimo; Francesco E Pontieri
Journal:  J Neural Transm (Vienna)       Date:  2008-12-17       Impact factor: 3.575

6.  The effect of citalopram on gene expression profile of Alzheimer lymphocytes.

Authors:  András Palotás; László G Puskás; Klára Kitajka; Miklós Palotás; József Molnár; Magdolna Pákáski; Zoltán Janka; Botond Penke; János Kálmán
Journal:  Neurochem Res       Date:  2004-08       Impact factor: 3.996

7.  Dopamine receptors in human lymphocytes: radioligand binding and quantitative RT-PCR assays.

Authors:  Galina P Kirillova; Rebecca J Hrutkay; Michael R Shurin; Galina V Shurin; Irina L Tourkova; Michael M Vanyukov
Journal:  J Neurosci Methods       Date:  2008-08-05       Impact factor: 2.390

Review 8.  Immunomodulatory Effects Mediated by Dopamine.

Authors:  Rodrigo Arreola; Samantha Alvarez-Herrera; Gilberto Pérez-Sánchez; Enrique Becerril-Villanueva; Carlos Cruz-Fuentes; Enrique Octavio Flores-Gutierrez; María Eugenia Garcés-Alvarez; Dora Luz de la Cruz-Aguilera; Emilio Medina-Rivero; Gabriela Hurtado-Alvarado; Saray Quintero-Fabián; Lenin Pavón
Journal:  J Immunol Res       Date:  2016-10-04       Impact factor: 4.818

9.  Influence of chronic L-DOPA treatment on immune response following allogeneic and xenogeneic graft in a rat model of Parkinson's disease.

Authors:  Ludivine S Breger; Korbinian Kienle; Gaynor A Smith; Stephen B Dunnett; Emma L Lane
Journal:  Brain Behav Immun       Date:  2016-11-15       Impact factor: 7.217

Review 10.  The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders.

Authors:  Sonia Mediouni; Maria Cecilia Garibaldi Marcondes; Courtney Miller; Jay P McLaughlin; Susana T Valente
Journal:  Front Microbiol       Date:  2015-10-23       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.